Loading…
← CockpitCompetitor Analysis › CMPS COMPASS Pathways Plc Sponsored ADROpen in the cockpit ↗

COMPASS Pathways Plc Sponsored ADRCMPSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.

Momentum laggard 12
Mkt cap
$1.15B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$33.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.7%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$8.12
1D+1.8%
1W-12.7%
1M-31.8%
3M-41.2%
6M-25.3%
YTD+17.7%
1Y+52.4%
ATR %9.4%
Beta1.83
52w lowhigh48.8% off high

What COMPASS Pathways Plc Sponsored ADR does

Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.

Has no product to sell yet, so it is funded by share sales, and its value rests on getting COMP360 approved and then paid for by insurers. The treatment is a supervised dosing session with trained therapists rather than a pill taken at home, so a launch would need clinics set up for it. The company is based in London.

Products and services

  • COMP360 (synthetic psilocybin, treatment-resistant depressio
  • Pipeline in PTSD

Customers

  • Psychiatrists/mental health clinics (post-approval

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Psychedelic-assisted mental health…

What could go right

  • Pivotal trial data readouts
  • Growing psychedelic therapy regulatory acceptance

What could go wrong

  • Clinical trial failure risk
  • Complex in-clinic delivery and reimbursement model

Moat: narrow (IP / patents, regulatory licence). First mover with patented synthetic psilocybin formulation and specialized therapy-delivery infrastructure.

Headquarters: London, UK · Founded: 2016 · Employees: 156

Named competitors

  • MindMed private or unlisted
  • Cybin private or unlisted
  • atai Life Sciences ATAI

COMPASS Pathways Plc Sponsored ADR at a glance

Size COMPASS Pathways Plc Sponsored ADR (CMPS) is a United States Health Care company (Biotechnology) with a market value of $1.15B, the 2146th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.12 on 18 Nov 2026.

Performance Over six months the shares fell 25.3%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.

Short interest Short interest is 12.1% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 81CMPS 70
Six months, rebased to 100: COMPASS Pathways Plc Sponsored ADR against the median of its 20 peers (local-currency closes).

COMPASS Pathways Plc Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$5,991-$216,505-$233,098-$242,938-$329,796
EBITDA-$198M-$179M-$178M-$137M-$110M
Net income-$280M-$289M-$155M-$119M-$91.4M
Free cash flow-$177M-$158M-$119M-$97.8M-$106M
Capital expenditure$0$0$0$66,256$595,632
Total debt$54.4M$35.0M$32.2M$33.0M$1.93M

Quarterly statements and history in the cockpit →

COMPASS Pathways Plc Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%AKUMSVORMLYS688739JBIO0004039606301207002030300482ANROINBXTSHANVAXSGP688276NUVBCMPS6-month return →1-month return →
Up and to the right = strong over both horizons. COMPASS Pathways Plc Sponsored ADR is the large dot.

COMPASS Pathways Plc Sponsored ADR competitors and peer comparison

Head to head with its named competitors (CMPS vs ATAI)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
COMPASS Pathways Plc Sponsored ADR CMPS$1.15B-25%n/an/an/an/a
AtaiBeckley ATAIn/a+81%n/an/an/an/a

How COMPASS Pathways Plc Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

COMPASS Pathways Plc Sponsored ADR against its 20 peers (data as of 18 Nov 2026)
MeasureCMPSPeer medianRank in peer set
1-month return-31.8%-8.6%3rd lowest of 21
6-month return-25.3%-17.5%7th lowest of 19
Distance from 52-week high-48.8%-45.0%9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a

Questions

Who are COMPASS Pathways Plc Sponsored ADR's main competitors?
Named competitors: MindMed (private or unlisted), Cybin (private or unlisted), atai Life Sciences (ATAI). The cockpit's measured peer set (industry) also includes Kardigan (KARD), Akums Drugs and Pharmaceuticals (AKUMS.NS), Vor Biopharma (VOR), Mineralys Therapeutics (MLYS), Liaoning Chengda Biotechnology (688739.SS), Jade Biosciences (JBIO).
How has COMPASS Pathways Plc Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned -25.3% against -17.5% for the median peer; over one year +52.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.